Sun Pharma Licenses Lerodalcibep Worldwide Ex-US, China

Business Standard Markets · stocks

Sun Pharma has entered an exclusive licensing agreement with LIB Therapeutics Inc. to commercialize and manufacture lerodalcibep globally, excluding the United States and China. Lerodalcibep, a once-monthly PCSK9 inhibitor for lowering LDL-C, is approved in the EU as Lyrokaul and in the US as Lerochol. This partnership aims to address a significant unmet need in cardiovascular care, as many high-risk patients do not meet LDL-C goals.